BPH tedavisinde 5-Alfa redüktaz inhibitörlerine ne kadar süre ile devam edilmelidir?
PDF
Cite
Share
Request
Review
P: 30-32
December 2010

BPH tedavisinde 5-Alfa redüktaz inhibitörlerine ne kadar süre ile devam edilmelidir?

Bull Urooncol 2010;9(4):30-32
1. Ege Üniversitesi Tip Fakültesi, Üroloji Anabilim Dali, Izmir
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Dihydrotestosterone has an important role in the etiology and progression of BPH. Reduction of lower urinary tract symptoms and slowing down the progression of the disease is possible by the inhibition of 5-AR enzyme that converts testosterone to dihydrotestosterone. The main disadvantage of the treatment is effect of drug therapy occurs around six months. Efficiency of these agents are proved in many scientific studies and neither their long term safety nor their effect to reduce hemorrhage in patients undergoing surgery should not be forgotten.

Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House